Harrow Announce Manufacture Of First Of Three Commercial-Scale Process Performance Qualification Batches Of Triesence For Visualization During Vitrectomy And Ocular Inflammatory Conditions, Harrow Says Second & Third Required PPQ Batches Are Scheduled
Portfolio Pulse from Benzinga Newsdesk
Harrow has announced the manufacture of the first of three commercial-scale Process Performance Qualification (PPQ) batches of Triesence, a product used for visualization during vitrectomy and ocular inflammatory conditions. The second and third required PPQ batches are scheduled.
June 20, 2024 | 11:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harrow has successfully manufactured the first commercial-scale PPQ batch of Triesence, with the second and third batches scheduled. This progress is crucial for the product's market readiness and regulatory approval.
The successful manufacture of the first PPQ batch and the scheduling of subsequent batches indicate significant progress towards the market readiness and regulatory approval of Triesence. This is likely to positively impact Harrow's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100